OmniAb, Inc. SEC Filings

OmniAb, Inc. reported Q2 2026 revenue of $13.4 million, up from $3.9 million a year earlier, driven mainly by milestone revenue along with higher service and xPloration sales. Net loss narrowed to $5.9 million, or $0.05 per share, while total costs and operating expenses were flat at $20.1 million and cash costs were $13.3 million.

For the first half of 2026, revenue was $27.8 million compared with $8.1 million in 2025, and net loss improved to $13.6 million, or $0.11 per share. Total costs and operating expenses were $42.3 million, including higher non-cash amortization tied to a prior impairment. Cash, cash equivalents and short-term investments totaled $52.0 million as of June 30, 2026.

OmniAb raised 2026 guidance, now expecting revenue of $32–$36 million, GAAP costs and operating expenses of $84–$88 million, non-GAAP cash costs of $51–$55 million, and year-end cash of $37–$41 million with an effective tax rate of approximately 0%. The company highlighted 110 active partners, 425 active programs, and multiple partner-led assets advancing into or toward Phase 3 studies.

OmniAb, Inc. granted its Chief Operating Officer, Nwachuku Amechi Ekeke, a stock option covering 800,000 shares of common stock at a $1.9800 per-share exercise price, expiring on August 1, 2036. The option vests as to 1/8 of the shares on the six-month anniversary of the grant date and as to 1/48 of the shares each month thereafter for 42 months, beginning on August 1, 2026, subject to his continued service.

OmniAb, Inc. officer Nwachuku Amechi Ekeke, the company’s Chief Operating Officer, filed an initial statement of beneficial ownership as a reporting person. The filing lists no reportable transactions and shows no equity holdings or derivative positions currently reported for this individual.

OmniAb, Inc. appointed Amechi Nwachuku as Chief Operating Officer effective July 13, 2026. He is a life sciences executive with over two decades of commercial and leadership experience at Thermo Fisher Scientific, Danaher operating companies SCIEX and Beckman Coulter Diagnostics, Johnson & Johnson, and Bayer, and holds both an M.B.A. and B.S. from MIT.

His compensation includes an initial annual base salary of $445,000, eligibility for an annual target bonus equal to 45% of base salary (prorated for 2026), and a $20,000 signing bonus. Effective August 1, 2026, he received stock options to purchase 800,000 shares of OmniAb common stock under the 2022 Incentive Award Plan, with 12.5% vesting six months after grant and the balance vesting in equal monthly installments thereafter, subject to continued service, at an exercise price equal to the Nasdaq closing price on the grant date.

He participates in the OmniAb Severance Plan, which provides cash severance equal to base salary for a period of two months plus one week per year of service and continued health coverage at existing cost levels during that period upon an involuntary termination without cause, subject to a release. He has a separate change in control severance agreement that, if he is terminated without cause or resigns for good reason within 24 months after a change in control, provides a lump-sum benefit equal to one times annual base salary, plus one times the greater of the maximum target bonus for the year of termination or change in control, plus 12 times his monthly health coverage premium. In that case, all time-based equity awards fully vest and the post-termination stock option exercise period extends to nine months, not beyond the original expiration date, conditioned on a general release of claims.

OmniAb director Carolyn R. Bertozzi reported equity-based compensation activity. She exercised 20,000 Restricted Stock Units into Common Stock, bringing her direct holdings to 113,308 shares. She also received grants of 40,000 stock options at an exercise price of $2.03 and 20,000 new RSUs, each unit representing one share of Common Stock. The RSUs and options vest in full on the earlier of the next annual stockholder meeting or the first anniversary of their grant date.

OmniAb director Jennifer R. Cochran reported equity compensation-related transactions. On June 17, 20,000 Restricted Stock Units vested and were converted into 20,000 shares of Common Stock, bringing her direct holdings to 185,274 shares. She also received 40,000 stock options with a $2.03 exercise price and 20,000 new RSUs, each tied to one share of Common Stock, all vesting in full on the earlier of the next annual stockholder meeting or the first anniversary of the grant date.

OmniAb, Inc. director Steven C. Crouse reported equity compensation-related transactions with no share sales. He exercised derivative rights to acquire 20,000 shares of Common Stock, bringing his direct holdings to 33,333 shares. He also received 40,000 stock options at a $2.03 exercise price and 20,000 Restricted Stock Units, which vest based on the next annual stockholder meeting or the first anniversary of grant.

OmniAb director Philip J. Gotwals reported equity compensation and vesting activity. He acquired 20,000 shares of Common Stock through the vesting and conversion of previously granted Restricted Stock Units and now holds 33,333 shares directly. He also received 40,000 new stock options with a $2.03 exercise price and 20,000 new RSUs, which vest in full on the earlier of the next annual stockholder meeting or the first anniversary of their grant dates.

OmniAb, Inc. director John L. Higgins reported compensation-related equity activity with no open-market trades. On June 17, 2026, he exercised 20,000 Restricted Stock Units into Common Stock, bringing his direct holdings to 2,962,320 shares. He also received 40,000 stock options at an exercise price of $2.03 per share, expiring on June 17, 2036, and a new grant of 20,000 RSUs, which vest in full on the earlier of the next annual stockholder meeting or the first anniversary of their grant.